MERIT Oncology Symposium

MERIT Oncology Symposium

June 27, 2023 | Cambridge, MA

Tuesday, June 27th I 4 – 8:30 PM

  • Heavy hors d’oeuvres & drinks
  • Insightful presentations by industry experts
  • Key opportunity to network with industry peers and oncology KOLs

Join us at the MassBio Hub in Cambridge on June 27th for an oncology-focused networking and educational event hosted by MERIT. There will be great food and drinks provided along with insightful presentations by industry experts. Don’t miss Dr. Jan Cerny’s, MD, PhD, FACP, talk at 4:30 pm on how pandemic shifts have shaped hematological oncology trials going forward. Dr. Jimmy Belotte, MD, PhD, FACOG, will also be speaking at 5:15 pm to address the opportunities and challenges for diversity in clinical trials. This will be a key opportunity to network with industry peers and oncology KOLs.


4:30 Dr. Jan Cerny, MD, PhD, FACP
Topic: How Hematological Oncology Trials Have Been Impacted or Shaped by the Pandemic and How We May Run Trials Going Forward, includes Q/A
5:15 Dr. Jimmy Belotte, MD, PhD, FACOG
Topic: Opportunities and Challenges for Diversity in Clinical Trials, includes Q/A
6:00 Jim Golando
Brief MERIT overview

We will be serving heavy hors d’oeuvres and drinks before and after the presentations.

Space is Limited!



700 Technology Square 5th floor

Cambridge, MA 02139


Dr. Jimmy Belotte, MD, PhD, FACOG

Dr. Belotte is the Medical Director at GlaxoSmithKline R&D Oncology Clinical Development and Diversity, Equity and Inclusion (DE&I) lead for the department. He is a National Institute of Health (NIH) Scholar, and physician scientist by training. Dr. Belotte is a board-certified Obstetrician and Gynecologist and former Associate Professor of Obstetrics and Gynecology at both Wayne State University School of Medicine and Albert Einstein-Montefiore College of Medicine. He has spent over a decade conducting ovarian cancer research with multiple publications in peer-reviewed journals. Dr. Belotte’s mission is to better women’s health by providing high quality, evidenced-based, safe, and cost-effective care, advancing the field through innovation, research, and advocacy.

Dr. Jan Cerny, MD, PhD, FACP

Dr. Cerny is an Associate Professor at the University of Massachusetts Chan Medical School, Director of the Leukemia Program, and Co-Director of the Bone Marrow Transplant Program. His research focus is in translational and clinical research in Leukemia including research to improve our understanding of the biology of leukemia stem cells and their microenvironment, and to identify potential targets. His clinical research interests include evaluating novel therapies for patients with hematological malignancies including targeted, cellular, and immune approaches.

Jim GolandoClinical Operations and Imaging Clinical Trial Expert

Jim Golando has 30+ years of experience in the pharmaceutical and biotech industries. His expertise ranges from Phase I through late-stage development and lifecycle management, with particular strengths in imaging clinical trials, clinical research, clinical operations, procurement/outsourcing, project/team leadership, and project management. He has overseen the operational and developmental planning and execution of global clinical trials in imaging, oncology, respiratory, endocrine, anti-infectives, and cardiology. Jim held senior leadership positions as Chief of Operations at Ora, Inc. and Median Technologies. He was previously VP of Medical Affairs at BioClinica, and held clinical operation positions at Schering-Plough, Novartis, and Hoffman-La Roche. Jim founded Golando Advisory Group and has been consulting since 2012.


Transparent communication with prompt access to in-house experts

Deep bench of experienced and tenured staff trained in industry sponsored clinical trials, with a dedicated team for every project

We are often able to provide competitive pricing and shortened timelines for our sponsors and partners through efficiences gained from decades of experience

Proven track record supporting FDA approval of numerous products

EXCELSIORTM, our cloud-based software solution, is designed for imaging studies and is FDA 510(k) cleared as well as HIPAA, 21 CFR Part11, and GDPR compliant. EXCELSIOR enhances the efficiency and accuracy of your imaging data collection and interpretation

MERIT’s innovative respiratory software application, CompleClinical®, simplifies and streamlines the pulmonary clinical trial process, improving the efficiency and accuracy of data capture, management, and grading of spirometry data

Personalized attention, scalable solutions, and reliable clinical trial endpoint services

Some companies tend to overpromise and underdeliver, which puts your study success at risk. If you’re looking for a clinical trial endpoint services provider that will value your partnership and make your study a priority, consider MERIT.



Our Partners